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Abstract. Background/Aim: This study aimed to elucidate
the detailed characteristics of CYP3A5 expression and the
association between CYP3A5 expression and clinical
outcomes in patients with renal cell carcinoma (RCC).
Patients and Methods: This study retrospectively enrolled
124 Japanese patients with RCC treated at the Okayama
University Hospital. The commonest CYP3A5 gene
polymorphism, CYP3A5*3, and expression levels of CYP3A5
mRNA and protein in each tissue were examined. Results:
Expression of CYP3A5 mRNA and protein in RCC tissues
was significantly down-regulated compared to that in
adjacent normal tissues. High level of CYP3A5 mRNA
expression significantly extended cancer-specific survival
(p=0.004) and overall survival (p=0.002). The CYP3A5
mRNA expression level was identified as a significant
independent prognostic factor for both cancer-specific
survival and overall survival. Conclusion: CYP3A5 could
serve as a potential marker for prognostication and
treatment planning for patients with RCC.
Renal cell carcinoma (RCC) is the commonest cancer of the
kidney and comprises approximately 90% of all cases of
kidney cancer (1). RCC is estimated to account for 2% of
new cancer cases or cancer deaths worldwide (2, 3).
Advances in cancer therapy have improved the 5-year
survival rates for RCC, although the overall prognosis for
RCC remains unsatisfactory, at approximately 65% of the
current 5-year survival rates for RCC (4). Moreover, the
global incidence of RCC has been gradually increasing (5).
Cytochrome P450 (CYP) 3A is the most abundant CYP
subfamily that is responsible for the metabolism of a large
number of substrates in humans. The major CYP3A isoform
is CYP3A4; however, three minor isoforms, CYP3A5,
CYP3A7, and CYP3A43, have been reported (6). Of these,
CYP3A5 is the most abundantly expressed enzyme of the
minor CYP3A isoforms in adults (6). The CYP3A5 gene is
highly polymorphic, which causes individual variations in
the expression of CYP3A5. The commonest allele
responsible for the variable protein expression of CYP3A5
is CYP3A5*3 (rs776746, 6986 A>G) (7). Individuals who are
homozygous for the CYP3A5*3 allele either express very
low levels of CYP3A5 protein or lack CYP3A5 protein
expression (7, 8). Interestingly, evidence from small cohort
studies indicate that CYP3A5, but not CYP3A4, is markedly
expressed in the normal kidney with a CYP3A5*1 allele (9,
10). Thus, CYP3A5 is considered to play a role in substrate
metabolism in the kidney.
Most studies on the role of CYP3A5 in cancer have
focused on the metabolism of exogenous agents, such as
anticancer drugs, in the liver and small intestine. Many
anticancer drugs are reported to be candidate substrates of
CYP3A5 (11, 12). In addition, evidence has shown that
CYP3A5 has several roles in cancer progression, via the
metabolism of endogenous or carcinogenic substrates, that
are independent of the metabolism of anticancer drugs (13).
2511
Correspondence to: Jun Matsumoto (ORCID iD: 0000-0001-7224-
108X), PhD, Department of Personalized Medicine and Preventive
Healthcare Sciences, Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho,
Kita-ku, Okayama 700-8558, Japan. Tel and Fax: +81 862357873,
e-mail: matsumotoj@okayama-u.ac.jp
Key Words: CYP3A5 protein, human, cytochrome P450 CYP3A,
renal cell carcinoma treatment outcome.
ANTICANCER RESEARCH 41: 2511-2521 (2021)
doi:10.21873/anticanres.15029
Relevance of CYP3A5 Expression on the Clinical 
Outcome of Patients With Renal Cell Carcinoma
JUN MATSUMOTO1, YUMI KOTERA1, SHOGO WATARI2, KOICHI TAKEUCHI1, 
HIDEO UEKI2, TOSHIHIRO KOYAMA3, KOICHIRO WADA2, 
MASACHIKA FUJIYOSHI1, YASUTOMO NASU2 and NORITAKA ARIYOSHI1
1Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan;
2Department of Urology, Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Okayama University, Okayama, Japan;
3Department of Pharmaceuticals Biomedicine, Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
Moreover, recent studies have suggested that CYP3A5 itself
acts as a tumor suppressor by regulating cell signaling (14,
15). Thus, CYP3A5 expression has been proposed as a
potential marker for cancer prevention and treatment.
However, the potential role of CYP3A5 in promoting or
inhibiting cancer progression may differ depending on the
type of cancer. Thus far, the detailed characteristics of
CYP3A5 expression in RCC and its clinical relevance in
RCC patients remain unknown despite the fact that renal
cells express CYP3A5. More information on CYP3A5
expression profiles in RCC may contribute to a better
understanding of the underlying malignant behavior and
metabolic capacity of RCC.
The aim of this study was to elucidate the detailed
expression profiles of CYP3A5 and the association between
CYP3A5 expression and clinical outcomes in RCC patients.
Unlike most previously reported studies that focused on either
the genotype or phenotype of CYP3A5 in cancer patients, this
study has clarified both genotypic and phenotypic
characteristics in RCC tissues. Moreover, to the best of our
knowledge, this study includes the largest number of samples
to directly elucidate the details of CYP3A5 expression
profiles and its clinical relevance in RCC patients. 
Patients and Methods 
Patients. This study retrospectively enrolled 124 Japanese RCC
patients who underwent surgery between March 2003 and December
2015 at the Okayama University Hospital and fulfilled the following
criteria: 1) no neoadjuvant drug therapy or radiotherapy, 2) no
history of other tumors, and 3) availability of detailed
clinicopathological data. The collected RCC tissues and the
corresponding adjacent normal kidney tissue specimens were stored
at −80˚C until analysis. Detailed information on patient
characteristics is listed in the Table I. The nuclear grade values of
participants were determined according to the General Rule for
Clinical and Pathological Studies on Renal Carcinoma (16). In the
samples with Fuhrman’s grading score, grades 1 to 3 corresponded
to Fuhrman’s grading, and Fuhrman’s grade 4 corresponded to grade
3 disease scoring by the general rule. Cancer-specific survival (CSS),
which is defined as death due to cancer-related problems, and the
overall survival (OS) was ascertained from the records at Okayama
University Hospital or the Okayama prefectural office or through a
phone call to the patient, other hospitals, or the relevant general
practitioner. This study was approved by the ethics committee of
Okayama University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences of Okayama University Hospital (approval
number: 1802–033) and was conducted in accordance with the
ethical principles stated in the Declaration of Helsinki. Patients
provided informed consent for study participation and were given
the opportunity to freely opt out of this study at any time.
Preparation of DNA, RNA, and protein from each tissue specimen.
RCC tissues or the adjacent normal tissues were sliced in half, and
each part was used separately for genomic DNA/total RNA isolation
and protein extraction, respectively. When the weight of tissue
specimens was less than 30 mg, the tissues were not divided and
only genomic DNA/total RNA was isolated without protein
extraction. Genomic DNA and total RNA isolation were carried out
using TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instruction. Total proteins from each tissue
were extracted by homogenizing with an extraction buffer
comprising 20 mM Tris-HCl (pH 7.4), 150 mM sodium chloride, 10
mM EDTA, 0.5% Triton X-100, and 0.5% sodium cholate, followed
by two cycles of freezing and thawing. After centrifugation for 15
min at 14,000 rpm at 4˚C, the supernatant was used as the protein
fraction.
CYP3A5*3 genotyping. CYP3A5*3 genotyping for each patient was
carried out by the PCR-restriction fragment length polymorphism
method with DraI (Takara, Shiga, Japan) and using specific primers
(forward, 5’-CTAACCATAATCTCTTTTAAGAGCTCTTTTGTC
TTTAA-3’; reverse, 5’-ACTTTGATCATTATGTTATGTAATCCA
TAC-3’) as described previously (17). Genomic DNA isolated from
adjacent normal kidney tissues was used as the template for
CYP3A5*3 genotyping.
Real-time PCR. Real-time reverse transcription PCR was carried out
using ReverTra Ace® qPCR RT Master Mix with gDNA Remover
(TOYOBO, Osaka, Japan) and THUNDERBIRD® SYBR qPCR Mix
(TOYOBO) with specific primers (forward, 5’-AAGTATGGAAAAAT
GTGGGGAAC-3’; reverse, 5’-CTGTAGGCCCCAAAGATGTC-3’)
according to the manufacturer’s instructions as described previously
(17). GAPDH mRNA expression was used as an internal standard
reference for CYP3A5 mRNA expression. 
Western immunoblot analysis. Western immunoblot analysis was
carried out as described previously (17). Polyclonal rabbit
antibodies against CYP3A5 (Abcam, Cambridge, England) and
GAPDH (Proteintech, Rosemont, IL, USA) were used as the
primary antibodies. Recombinant CYP3A5 (Corning Gentest,
Woburn, MA, USA) was used as a positive control for the specific
detection of CYP3A5. GAPDH protein expression was used as an
internal standard reference for CYP3A5 protein expression. 
Microarray dataset analysis. Microarray datasets from the Gene
Expression Omnibus (GEO) database at the National Center for
Biotechnology Information (https://www.ncbi.nlm.nih.gov/geo/)
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Table I. Demographics and clinical characteristics of the study
participants.
Characteristics                                       Patient              (Range or %)
                                                               number 
                                                              (n=124)
Age, years (mean±SD)                      64.19±11.55            (27 to 87)
Gender (male/female)                              77/47                 (62.1/37.9)
Tumor stage (T1/T2/T3)                       77/12/35           (62.1/9.7/28.2)
Lymph node status (N0/N1/N2)            115/3/6             (92.7/2.5/4.8)
Metastasis (M0/M1)                               104/20                (83.9/16.1)
TNM stage (Ⅰ/Ⅱ/Ⅲ/Ⅳ)                      74/11/19/20    (59.7/8.9/15.3/16.1)
Nuclear grade (1/2/3)                           22/71/31          (17.7/57.3/25.0)
Histological type                                 98/6/10/10       (79.0/4.8/8.1/8.1)
(clear cell/papillary/
chromophobe/mix or others)
were used to determine the difference in the expression levels of
CYP3A5 mRNA between normal kidney tissues and RCC tissues.
The database included only two datasets from very small cohorts
(GSE781 and GSE6344) that contained paired data for RCC tissues
and adjacent normal tissues. 
Statistical analysis. Statistical analyses were performed using
GraphPad Prism 5 (GraphPad, San Diego, CA, USA) and JMP® 15
(SAS Institute Inc., Cary, NC, USA). Paired Student’s t-test or
Mann–Whitney U-test test were used for the comparison of the
means of the two groups. One-way ANOVA followed by Tukey’s
post hoc test was used for multiple comparisons. The cutoff value
for CYP3A5 mRNA expression was selected by using receiver
operating characteristic curve analysis, and the highest value with
both maximum sensitivity and specificity on the curve for survival
of patients was applied. Associations between clinical characteristics
and information on CYP3A5 expression were evaluated using the
chi-square or Fisher’s exact test. Survival curves were produced
using the Kaplan–Meier method, and differences in survival rates
were compared using the log-rank test. Univariate and multivariate
Cox analyses were performed to identify independent prognostic
factors. All tests were two-tailed, and p<0.05 indicated statistical
significance.
Results 
CYP3A5 expression profiles in RCC tissues and adjacent
normal tissue specimens based on CYP3A5*3 genotype. The
expression of CYP3A5 protein was detected in RCC tissues
and adjacent normal tissues (Figure 1A). To assess the details
of CYP3A5 expression profiles, CYP3A5 mRNA and protein
expression levels were analyzed based on the CYP3A5*3
genotypes (Figure 1B to E). In the adjacent normal tissues,
CYP3A5 mRNA expression with the genotypes of *1/*1 and
*1/*3 was significantly higher than that of the *3/*3
genotype. In RCC tissues, CYP3A5 mRNA expression with
the genotypes *1/*1 and *1/*3 was significantly higher than
that with the *3/*3 genotyped; moreover, a significant
difference in CYP3A5 mRNA expression between *1/*1 and
*1/*3 genotypes was observed. The results for CYP3A5
protein expression profiles were almost the same as those for
CYP3A5 mRNA. In the adjacent normal tissues, the protein
expression of CYP3A5 with genotypes *1/*1 and *1/*3 was
significantly higher than that of the *3/*3 genotype. In RCC
tissues, the protein expression of CYP3A5 was significantly
higher in *1/*1 than in *1/*3 and *3/*3; however, there was
no significant difference in CYP3A5 protein expression
between the *1/*3 and *3/*3 genotypes. Significant
correlations were observed among CYP3A5 mRNA
expression level and its protein expression level in both
adjacent normal tissues and RCC tissues (Table II). The
allele frequency of CYP3A5*3 was 0.79, which was in the
Hardy–Weinberg equilibrium. The concordance rates of the
CYP3A5*1 genotype with the CYP3A5 protein expression in
the adjacent normal tissues and RCC tissues were 86.4%
(n=88) and 70.2% (n=104), respectively.
Difference in the level of CYP3A5 expression between RCC
tissues and the adjacent normal tissues. In two datasets
(GSE781, n=7; CSE6344, n=10) in the GEO database, the
expression level of CYP3A5 mRNA in RCC tissues tended
to be or was significantly lower than that in the adjacent
normal tissues (Figure 2A and B). These results from the two
datasets were in accordance with those from the cohort of
this study. The expression level of CYP3A5 mRNA in RCC
tissues was significantly lower than that in the adjacent
normal tissues (Figure 2C). With regard to the level of
CYP3A5 protein expression, there was a significant
difference in the level of CYP3A5 protein expression
between RCC tissues and adjacent normal tissues (Figure
2D). Frequent down-regulation of CYP3A5 protein
expression was observed in RCC tissues compared with that
in the adjacent normal tissues (Figure 2E).
Correlation between CYP3A5 expression and
clinicopathological parameters in RCC patients. From
results of the significant correlation between CYP3A5
mRNA and its protein expressions and low number of
patients who expressed the CYP3A5 protein due to down-
regulation of CYP3A5 protein expression, several
clinicopathological parameters of RCC patients were
assessed for correlation with the CYP3A5 mRNA levels
(Table II). In the adjacent normal tissues, CYP3A5 mRNA
was not correlated with any clinicopathological parameters.
In RCC tissues, high levels of CYP3A5 mRNA expression
were significantly correlated with lymph node status and
histological types. With regard to the down-regulation of
CYP3A5 mRNA expression in RCC tissues, decreased
CYP3A5 mRNA expression in RCC tissues was significantly
correlated with a higher TNM stage and histological types.
Impact of CYP3A5 expression on clinical outcome in RCC
patients. The CYP3A5 mRNA level was evaluated to
determine whether they correlated with clinical outcomes in
RCC patients (Figure 3). In the adjacent normal tissues, there
were no differences in CSS and OS with regard to the levels
of CYP3A5 mRNA expression. On the other hand, patients
with high CYP3A5 mRNA expression levels in RCC tissues
exhibited significantly longer CSS and OS, indicating that the
level of CYP3A5 expression possibly correlated with clinical
outcome in RCC patients. With regard to changes in the
levels of CYP3A5 mRNA expression, decreased CYP3A5
mRNA expression also significantly shortened CSS and OS.
Next, we investigated the prognostic value of the level of
CYP3A5 mRNA expression in RCC tissues (Table III).
Univariate Cox analysis identified TNM stage as a
prognostic risk factor for CSS, whereas level of CYP3A5
mRNA expression tended to be a significant risk factor. On
the other hand, TNM stage and the level of CYP3A5 mRNA
expression were identified as significant prognostic risk
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factors for OS in univariate Cox analysis. Based on the
results for univariate Cox analysis, the number of events in
the present study, and the results from a previous paper from
similar cohorts (18), we further analyzed two variables,
TNM stage and level of CYP3A5 mRNA expression, in
multivariate Cox analysis. The results showed that the level
of CYP3A5 mRNA expression was an independent
prognostic factor for CSS and OS in RCC patients.
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Figure 1. CYP3A5 mRNA and protein expression based on CYP3A5*3 genotype in RCC tissues and the adjacent normal tissues. (A) Representative
pattern of CYP3A5 protein expression in adjacent normal tissues (N) and RCC tissues (T). Proteins (20 µg) were analyzed by Western immunoblot
analysis. PC, positive control (0.5 fmol). (B) and (C), the level of CYP3A5 mRNA expression in adjacent normal tissues (N; B) and RCC tissues (T;
C). The expression level is presented as the ratio of the average value of CYP3A5 mRNA expression in the adjacent tissues. (D) and (E), the level
of CYP3A5 protein expression in adjacent normal tissues (N; D) and RCC tissues (T; E). The expression levels are presented as mean±SD. ***,
**, *, and “ns” indicate p<0.001, p<0.01, p<0.05, and not significant, respectively.
Discussion
Currently, CYP3A5 expression in cancer is in the spotlight
(14, 15, 19-21). Herein, we first elucidated the detailed
expression of CYP3A5 in combination with the CYP3A5*3
genotypes and CYP3A5 mRNA expression in RCC tissues
using the largest number of samples as compared with other
papers. In many previous reports, there is no clear evidence
of renal CYP3A4 expression (9, 22, 23). In concordance
with those results, we did not find a detectable CYP3A4
protein expression in both RCC tissues and the adjacent
normal tissues (n=20, data not shown). Thus, the main
CYP3A isoform expressed in the kidney is CYP3A5, and not
CYP3A4. Therefore, clarifying the detailed expression of
CYP3A5 in RCC tissues was valuable in this study.
The allele frequency of CYP3A5*3 in this study was
similar to that in previous reports from the Japanese
population (24, 25). Nonetheless, CYP3A5 protein
expression did not completely correspond to the CYP3A5*1
genotype in both the adjacent normal tissues and RCC
tissues. The concordance rates of CYP3A5 protein
expression with the CYP3A5*1 genotype in the kidney were
lower than those in the liver and small intestine, where
CYP3A5 protein expression was almost completely
correlated with the CYP3A5*1 genotype (8). Several
polymorphisms, such as CYP3A5*6 and *7, in the CYP3A5
gene that cause variations in the level of CYP3A5 protein
expression have been reported (6). However, most of these
polymorphisms were not observed or were rarely detected in
the Japanese population (25, 26). CYP3A5 is expressed to a
Matsumoto et al: CYP3A5 Expression in Patients With Renal Cell Carcinoma
2515
Table II. The association between CYP3A5 and clinicopathological characteristics.
Characteristics                               CYP3A5 mRNA in N,      p-Value     CYP3A5 mRNA in T,          p-Value           CYP3A5 mRNA,               p-Value
                                                                    n (%)                                                   n (%)                                                          n (%)
                                                        High                 Low                              High                Low                            Increasing           Decreasing
Total number                                                 88                                                          104                                                            124                 
CYP3A5 genotype
   *1/*1 and *1/*3                      30    (88.2)      4       (7.4)      <0.001    33     (41.6)       5       (22.2)     0.060       -           -             -            -               -
   *3/*3                                         4     (11.8)     50     (92.6)                    47     (58.4)      19     (77.8)                      -           -             -            -               
CYP3A5 protein expression
   Yes                                           20    (58.8)      2       (3.7)      <0.001     11     (13.8)       0        (0.0)      0.001       -           -             -            -               -
   No                                            14    (41.2)     52     (96.3)                    69     (86.2)      24    (100.0)                     -           -             -            -               
Age, years
   <65                                           18    (52.9)     23     (42.6)      0.343     36     (45.0)      12     (50.0)     0.667      22      (45.8)       35      (46.1)      0.981
   ≥65                                           16    (47.1)     31     (57.4)                    44     (55.0)      12     (50.0)                    26      (54.2)       41      (53.9)           
Gender
   Male                                         20    (58.8)     33     (61.1)      0.831     51     (63.8)      16     (66.7)     0.793      17      (35.4)       28      (36.8)      0.872
   Female                                     14    (41.2)     21     (38.9)                    29     (36.2)       8       (33.3)                    31      (64.6)       48      (63.2)           
Tumor stage
   T1                                            21    (61.8)     34     (63.0)      0.910     50     (62.5)      13     (54.2)     0.148      34      (70.8)       43      (56.6)       0.111
   T2+T3                                      13    (38.2)     20     (37.0)                    30     (37.5)       11      (45.8)                    14      (29.2)       33      (43.3)           
Lymph node status
   N0                                            32    (94.2)     51     (94.4)      1.000     76     (95.0)      19     (79.2)     0.029      47      (97.9)       68      (89.5)      0.152
   N1+N2                                      2      (5.8)       3       (5.6)                       4       (5.0)        5       (20.8)                     1        (2.1)         8       (10.5)           
Metastasis
   M0                                           29    (85.3)     46     (85.2)      1.000     69     (86.3)      17     (70.8)     0.095      43      (89.6)       61      (80.3)      0.169
   M1                                            5     (14.7)      8      (14.8)                     11     (13.7)       7       (29.2)                     5       (10.4)       15      (19.7)           
TNM stage
   Ⅰ+Ⅱ                                           22    (64.7)     39     (72.2)      0.459     57     (71.3)      13     (54.2)     0.124      38      (79.2)       47      (61.8)      0.043
   Ⅲ+Ⅳ                                      12    (35.3)     15     (27.8)                    23     (28.7)       11      (45.8)                    10      (20.8)       29      (38.2)           
Nuclear grade
   1+2                                           25    (73.5)     46     (85.2)      0.182     62     (77.5)      15     (62.5)     0.152       9       (18.4)       22      (28.9)      0.202
   3                                                9     (26.5)      8      (14.8)                    18     (22.5)       9       (37.5)                    39      (81.6)       54      (71.1)           
Histological type
   Clear cell                                 27    (79.4)     39     (72.2)      0.444     67     (83.8)      12     (50.0)     0.001      43      (89.6)       55      (72.4)      0.022
   Other                                         7     (20.6)     15     (27.8)                    13     (16.2)      12     (50.0)                     5       (10.4)       21      (27.6)           
The number of samples was 88 and 104, which corresponded to samples of CYP3A5*3 genotype, CYP3A5 mRNA, and CYP3A5 protein obtained
from adjacent normal tissues and RCC tissues, respectively. CYP, Cytochrome P450; N, adjacent normal tissues; T, RCC tissues. Bold values indicate
statistical significance.
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Figure 2. Down-regulation of CYP3A5 expression levels in RCC tissues compared with that in the adjacent normal tissues. (A) and (B), difference
in the level of CYP3A5 mRNA expression between adjacent normal tissues (N) and RCC tissues (T) in two datasets from the GEO database (A,
GSE781; B, CSE6344). The expression level is presented as the ratio of the average value of CYP3A5 mRNA expression in the adjacent tissues.
(C) and (D), differences in the expression levels of CYP3A5 mRNA (C, n=124) and protein (D, n=78) between adjacent normal tissues (N) and
RCC tissues (T) in the cohort of this study. The expression levels are presented as mean±SE. (E), detailed expression changes of CYP3A5 protein
from adjacent normal tissues to RCC tissues. The total protein fraction of the paired sample with RCC tissues and the adjacent normal tissues was
78. Down, Up, and ND indicate down-regulation, up-regulation, and not detected, respectively.
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Figure 3. Impact of CYP3A5 mRNA expression on the survival of RCC patients. (A)–(D), Kaplan–Meier analysis of CSS and OS based on the
CYP3A5 mRNA expression in normal adjacent tissues (A and B) and RCC tissues (C and D). (E) and (F), Kaplan–Meier analysis of CSS (E) and
OS (F) based on changes in the expression levels of CYP3A5 mRNA. Incr. and Decr. indicate increasing and decreasing, respectively.
1.5-fold greater extent in the cortex than in the medulla of
the human kidney (23). However, there is no information on
the detailed position of malignant and adjacent normal
tissues that were used in this study, which is possibly related
to the disagreement between CYP3A5 protein expression and
CYP3A5*1 genotype in the kidney.
The difference in the level of CYP3A5 expression
between normal tissues and cancer tissues has been
determined in several types of cancer. The level of CYP3A5
expression in liver cancer and lung cancer tissues is lower
than that in normal tissues (14, 15, 21). On the other hand,
an increase in the level of CYP3A5 expression is observed
in ovarian, colorectal, and breast cancers (27-29). A recent
study has shown that there is no association between the
CYP3A5*3 genotype and risk of ovarian cancer (30),
indicating that the level of CYP3A5 expression does not
seem to affect some cancers, such as ovarian cancer. In RCC,
the level of CYP3A5 expression was down-regulated in most
cancer tissues as well as in liver and lung cancer tissues.
Several RCC tissues did not express CYP3A5, whereas
CYP3A5 expression was detected in the adjacent normal
tissues. Given the position of malignant and adjacent normal
tissues, the lower concordance rates of CYP3A5 protein
expression with the CYP3A5*1 genotype, especially in RCC
tissues, may be partly explained by this down-regulation. A
significant correlation between the expression levels of
CYP3A5 mRNA and CYP3A5 protein indicates that the
down-regulation of CYP3A5 protein seems to be
transcriptionally regulated in RCC tissues. The
transcriptional activity of CYP3A5 is possibly regulated by
several nuclear receptors, such as pregnane X receptor (PXR;
NR1I2), constitutive androstane receptor (CAR; NR1I3),
hepatocyte nuclear factor 4α (HNF4α; NR2A1), and
peroxisome proliferator-activated receptor alpha (PPARα;
NR1C1), all of which are expressed in the kidney (31-34).
These receptors activate the transcription of several targeted
genes, including CYP3A5, after binding to ligands (35-37).
Using datasets from the GEO database (GSE781 or
CSE6344), the mRNA expression levels of three of these
receptors, NR1I3, NR2A1, and NR1C1, in RCC tissues were
significantly lower than those in the adjacent normal tissues
(p<0.001 for NR1I3, p=0.002 for NR2A1, and p=0.002 for
NR1C1; data not shown), indicating that the expression of
these nuclear receptors might be involved in the regulation
of CYP3A5 expression in RCC.
The effects of down-regulation of CYP3A5 on cancer
cells were examined in liver and lung cancers, both in vitro
and in vivo. In liver cancer, elevated CYP3A5 expression in
cancer cells inhibits cell migration and invasion via
ROS/mTORC2/p-AKT signaling (14). CYP3A5-inducd ROS
accumulation inhibits AKT phosphorylation followed by a
decrease in mTORC2 kinase activity, suggesting that
CYP3A5 plays a protective role in cancer progression. In
lung cancers, CYP3A5 represses the activation of Smad1 to
inhibit lung cancer metastasis by interacting with ATOH8
which is a transcription factor that could increase the
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Table III. Univariate and multivariate Cox analyses of cancer-specific survival and overall survival in 104 patients with RCC.
CSS                                                                                                                Univariate                                                              Multivariate
Variable                                                                    Unadjusted OR              95% CI              p-Value       Adjusted OR             95% CI              p-Value
Age, years                                      ≥65                             0.809                0.381 to 1.717           0.580                  -                             -                          -
Gender                                           Male                           1.430                0.629 to 3.248           0.382                  -                             -                          -
TNM stage                                     Ⅲ+Ⅳ                        4.750               1.748 to 10.130        <0.001              5.422             2.456 to 11.968        <0.001
Nuclear grade                                3                                 2.159                0.971 to 4.802           0.073                  -                             -                          -
Histological type                           Clear cell                   0.866                0.380 to 1.970           0.827                  -                             -                          -
CYP3A5 mRNA expression         High                           0.467                0.215 to 1.013           0.054              0.385              0.173 to 0.856           0.019
OS                                                                                                                  Univariate                                                              Multivariate
Variable                                                                    Unadjusted OR              95% CI              p-Value       Adjusted OR             95% CI              p-Value
Age, years                                      ≥65                             1.173                0.642 to 2.142           0.604                  -                             -                          -
Gender                                           Male                           1.176                0.621 to 2.229           0.615                  -                             -                          -
TNM stage                                     Ⅲ+Ⅳ                        3.229                1.748 to 5.963         <0.001              3.414              1.826 to 6.382         <0.001
Nuclear grade                                3                                 1.501                0.754 to 2.989           0.264                  -                             -                          -
Histological type                           Clear cell                   1.001                0.506 to 2.000           0.987                  -                             -                          -
CYP3A5 mRNA expression         High                           0.474                0.253 to 0.889           0.002              0.430              0.235 to 0.836           0.012
CSS, Cancer-specific survival; OS, overall survival; CYP, cytochrome P450; OR, odds ratio; CI, confidence interval. Bold values indicate statistical
significance.
phosphorylation of Smad1 (15). The interaction of CYP3A5
and ATOH8 results in a decrease in the Smad1
phosphorylation. The high CYP3A5 expression in these
cancer tissues significantly increased the survival duration
for these cancer patients, and CYP3A5 expression was
identified as an independent prognostic factor in multivariate
Cox analysis (14, 21). As our data were in accordance with
these results, the high level of CYP3A5 mRNA expression
significantly extended survival, and the level of CYP3A5
mRNA expression was identified as an independent
prognostic factor for RCC patients. Indeed, the
ROS/mTORC2/p-AKT signaling and Smad1 signaling
pathways are reported to be important for RCC progression
and for development of renal cells, respectively (38, 39).
Although further investigation is needed, CYP3A5 might
have a suppressive role in RCC by inducing ROS
accumulation and decreasing Smad1 phosphorylation as well
as in liver and lung cancers.
This study has two limitations, the number of events and
the number of samples that expressed the CYP3A5 protein.
Event numbers in RCC patients were low as the outcomes
of RCC patients were relatively better than those of
patients with other cancers, such as liver and lung cancers.
Most of the patients included in this study were in
relatively good condition because they could undergo
surgery, which may also be related to the low number of
events in this study. In addition, the number of patients
who expressed the CYP3A5 protein was considerably
lower than expected based on the allele frequency of
CYP3A5*1 in the Japanese population, especially in RCC
tissues, due to the discordance of CYP3A5 protein
expression with the CYP3A5*1 genotype and down-
regulation of CYP3A5 protein expression. Nonetheless,
our results suggest that expression levels of CYP3A5
mRNA in RCC tissues significantly correlated with its
protein expression and CYP3A5 protein expression is
transcriptionally regulated in RCC tissues. Thus, CYP3A5
may be involved in RCC progression and may have a
suppressive effect on RCC cells. 
Conclusion
This study determined the detailed characteristics of CYP3A5
expression in RCC. The expression of CYP3A5 in RCC
tissues was down-regulated compared to that in the adjacent
normal tissues. The level of CYP3A5 mRNA expression in
RCC correlated with several clinicopathological parameters
and survival in RCC patients, suggesting that CYP3A5 may
have a suppressive role in RCC. These findings provide basic
information on CYP3A5 expression in the kidney, may
facilitate better understanding of the importance of CYP3A5
in RCC, and may have implications for future prognostication
and treatment planning for patients with RCC. 
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